Methods of shielding implantable medical leads and implantable medical lead extensions

Information

  • Patent Grant
  • 10279171
  • Patent Number
    10,279,171
  • Date Filed
    Monday, July 20, 2015
    8 years ago
  • Date Issued
    Tuesday, May 7, 2019
    5 years ago
Abstract
A shield layer is added to an existing lead or lead extension by applying the shield layer to the lead body between the proximal contact and distal electrode of the lead body. The shield layer may be covered with an outer insulative layer. An inner insulative layer may be applied over the lead body prior to adding the shield layer and the outer insulative layer. The shield layer may have a terminator applied to the end of the shield layer to prevent migration of the shield layer through the outer insulative layer. The shield layer may be of various forms including a tubular braided wire structure or a tubular foil. The tubular braided wire structure may be applied to the lead body by utilizing the lead body as a mandrel within a braiding machine.
Description
TECHNICAL FIELD

Embodiments relate to implantable medical leads and implantable medical lead extensions. More particularly, embodiments relate to methods of shielding implantable medical leads and implantable medical lead extensions.


BACKGROUND

Implantable medical systems are used to provide stimulation therapy and/or physiological sensing for patients. The implantable medical system includes a stimulation or sensing device that is implanted at a convenient location. Implantable medical leads are routed between the site of implantation of the device and a target site where stimulation or sensing is to occur. Where the route is lengthy, an implantable medical lead extension is used to traverse a portion of that distance.


The implantable medical leads include one or more electrical contacts located near a proximal end of the lead. Where no extension is needed, the proximal end of the lead is physically connected to the stimulation or sensing device so that the proximal contacts of the lead are electrically coupled to electrical circuitry of the device. For scenarios where the implantable medical lead extension is used, then the proximal end of the lead is physically connected to a distal end of the extension where electrical connectors of the extension are coupled to the electrical contacts of the lead. The proximal end of the extension is physically connected to the stimulation or sensing device so that the proximal contacts of the extension are electrically coupled to electrical circuitry of the device. The leads also include one or more electrodes located near a distal end of the leads. Electrical conductors are present within the lead, and each electrical conductor is connected to a respective electrical contact and electrode to provide an electrical path for stimulation and/or sensed signals. Electrical conductors are also present within the extension, and each electrical conductor is connected to a respective electrical contact and distal connector to provide an electrical path for stimulation and/or sensed signals.


Because the lead and lead-extension combination extends over a significant distance within the body, each electrical conductor within the lead and extension is susceptible to receiving extraneous electromagnetic energy that produces electrical current on the electrical conductor. While most ambient conditions expose the lead and lead extension to insignificant levels of such extraneous electromagnetic energy, certain situations may create levels of extraneous electromagnetic energy that are of concern. An example of such a situation is a magnetic resonance imaging (MRI) scan. The MRI scan utilizes a high energy radio frequency (RF) electromagnetic signal. This RF signal may produce relatively large levels of electrical current on the electrical conductor of the lead and extension when the patient having the implantable medical system that includes the lead and/or lead extension combination undergoes the MRI scan. The relatively large electrical current that results from the high energy RF signal produces heating at the electrodes that may create discomfort and even dangerous tissue damage at the site within the body where the one or more electrodes of the lead are located.


It has been found that a shield layer within the lead reduces the amount of RF energy that reaches the electrical conductors, which in turn reduces the amount of current being coupled onto the electrical conductors and reduces the heating at the electrodes to acceptable levels. The manufacturing process of the lead has been altered to include a shield layer when the lead body is being manufactured by creating an inner jacket over the electrical conductor, then creating the shield layer on the inner jacket, and then creating an outer jacket over the inner jacket. The electrical contacts and electrodes are then installed about the inner jacket and are coupled to the electrical conductor to complete the leads. However, leads and extensions that have been constructed without such shield layers or other protective aspects remain vulnerable to the high levels of RF energy of the MRI scan or other situation.


SUMMARY

Embodiments address issues such as these and others by adding a shield layer onto the exterior surface of an insulative lead body of an existing lead having electrical contacts and electrodes already installed on that lead body. The shield layer is then covered by an insulative layer.


Embodiments provide a method of shielding an implantable medical lead. The method involves providing a shield layer onto an exterior surface of an insulative lead body of the implantable medical lead between an electrical contact on a proximal end of the insulative lead body and an electrode on a distal end of the insulative lead body with a proximal end of the shield layer being spaced distally from the electrical contact and with a distal end of the shield layer being spaced proximally from the electrode. The method further involves applying an outer insulative layer onto the shield layer while the shield layer is present on the exterior surface of the insulative layer with the outer insulative layer being located between the electrical contact and the electrode.


Embodiments provide a method of shielding an implantable medical lead. The method involves utilizing the implantable medical lead as a mandrel for a braiding machine to braid wires onto an insulative lead body of the implantable medical lead between an electrical contact on a proximal end of the implantable medical lead and an electrode on a distal end of the implantable medical lead with a proximal end of the shield layer being spaced distally from the electrical contact and with a distal end of the shield layer being spaced proximally from the electrode. The method further involves applying an outer insulative layer onto the braided wires while the braided wires are present on the insulative lead body of the implantable medical lead with the outer insulative layer being located between the electrical contact and the electrode.


Embodiments provide a method of shielding an implantable medical lead extension. The method involves providing a shield layer onto an exterior surface of an insulative lead body of the implantable medical lead extension between an electrical contact on a proximal end of the implantable medical lead extension and a distal end of the implantable medical lead extension with a proximal end of the shield layer being spaced distally from the electrical contact. The method further involves applying an outer insulative layer onto the shield layer with the outer insulative layer being located between the electrical contact and the distal end.


Embodiments provide a method of shielding an implantable medical lead extension. The method involves utilizing the implantable medical lead extension as a mandrel for a braiding machine to braid wires onto an insulative lead body of the implantable medical lead extension between an electrical contact on a proximal end of the implantable medical lead extension and a distal end of the implantable medical lead extension with a proximal end of the shield layer being spaced distally from the electrical contact. The method further involves applying an outer insulative layer onto the braided wires on the implantable medical lead extension with the outer insulative layer being located between the electrical contact and the distal end.


Embodiments provide an implantable medical lead that includes a lead body defining a lumen, a conductor within the lumen, a proximal contact coupled to a proximal area of the lead body, and a distal electrode coupled to a distal area of the lead body, with the conductor electrically coupling the proximal contact to the distal electrode. The implantable medical lead further includes an inner insulative layer coupled to the outer surface of the lead body, a shield layer positioned about the inner insulative layer and between the proximal contact and the distal electrode, and an outer insulative layer positioned about the shield layer and between the proximal contact and the distal electrode.


Embodiments provide an implantable medical lead extension that includes a lead body defining a lumen, a conductor within the lumen, a proximal contact coupled to a proximal area of the lead body, and a distal connector housing coupled to a distal area of the lead body with a distal connector positioned within the distal connector housing, the conductor electrically coupling the proximal contact to the distal connector. The implantable medical lead extension further includes an inner insulative layer coupled to the outer surface of the lead body, a shield layer positioned about the inner insulative layer and between the proximal contact and the distal connector housing, and an outer insulative layer positioned about the shield layer and between the proximal contact and the distal connector housing.





DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an example of an implantable medical system that includes a lead having an added shield layer according to various embodiments.



FIG. 2 shows an example of an implantable medical system that includes a lead extension having an added shield layer according to various embodiments.



FIG. 3 shows a lateral cross-sectional view of a lead or lead extension having an added shield layer according to various embodiments.



FIG. 4 shows an example of a logical flow of operations to add the shield layer to an existing lead or extension.



FIG. 5 shows an example of a braiding machine configuration for adding a braided shield layer to an existing lead.



FIG. 6 shows an example of a lead or lead extension having an added shield layer with a shield terminator.



FIG. 7 shows another example of a logical flow of operations to add the shield layer with a crimped shield terminator to an existing lead or extension.



FIG. 8 shows another example of a logical flow of operations to add the shield layer with an additional insulative shield terminator to an existing lead or lead extension.



FIG. 9 shows a lateral cross-sectional view of a lead or lead extension having an added shield layer and an added inner insulative layer according to various embodiments.



FIG. 10 shows another example of a logical flow of operations to add the shield layer and an inner insulative layer to an existing lead or extension.





DETAILED DESCRIPTION

Embodiments provide a shield layer for an existing implantable lead and/or implantable lead extension. This provides a method of manufacturing a lead or extension with a shield layer where a conventional manufacturing technique may be used to create a complete lead or lead extension and then the shield layer is added as a subsequent process. This further provides the ability to retrofit the shield layer to leads and lead extensions that have already been constructed and are present in available inventory so that this existing inventory is made safer for MRI scans.



FIG. 1 shows one example of an implantable medical system 100 that includes an implantable medical device 102 coupled to an implantable medical lead 110. A proximal end 112 of the lead 110 is present within a connection block 104 of the medical device 102 where electrical contacts 114 of the lead 110 are electrically connected to connectors 106 of the connection block 104. The connectors 106 are electrically coupled to stimulation and/or sensing circuitry 108 within a housing 103 of the medical device 102. A distal end 116 of the lead is routed to the stimulation site where electrodes 118 on the distal end 116 provide the stimulation signals to the tissue and/or sense signals from the tissue. Electrical conductors are present inside the lead 110 to electrically connect the contacts 114 with the electrodes 118.


According to the embodiment shown, the lead 110 has an added shield layer 122 that has been applied to an existing outer layer 120 of the lead body of the lead 110. This shield layer 122 may be of various forms such as a tubular structure of braided conductive wires that have been overbraided atop the existing outer insulative layer 120, a tubular conductive foil structure, and the like. For a braided shield, the wires of the braid may be a conductor such as a biocompatible metal like tantalum, titanium, and the like. For a foil shield, the foil may be a conductor such as biocompatible metal like tantalum, titanium, and the like.


Where the shield layer 122 is a braided wire shield as shown in FIG. 1, the braid may be created with a variety of shield parameters. Examples of shield parameters such as braid angle, wire cross-sectional shape and diameter, number of braid wires, braid depth, distance from shield termination to closest contact or electrode, and the like that may also be used for the embodiments being disclosed herein are described in U.S. patent application Ser. No. 13/264,067, which is incorporated herein by reference in its entirety.


As can be seen, the added shield layer 122 is present with a proximal end of the shield layer 122 starting distally of a most distal proximal contact 114 and ending proximally of a most proximal distal electrode 118. Likewise, an outer insulative layer 124 is applied atop the shield layer 122 with a proximal end of the outer insulative layer 124 starting distally of the most distal proximal contact 114 and ending proximally of the most proximal distal electrode 118 to thereby entirely cover the added shield layer 122. This prevents exposure of the added shield layer 122 to the tissue surround the lead 110.


While the shield layer 122 is not in direct contact with the tissue along the length of the lead 110, high frequency RF energy coupled onto the shield layer 122, such as during an MRI scan, may capacitively couple to the surrounding tissue to dissipate the RF energy over the length of the shield layer 122. Thus, there is a significant amount of tissue where the RF energy is being dissipated, rather than a small amount of tissue where the electrodes 118 are located. Furthermore, if desired, ground rings could be added atop the shield layer 122 where the ground rings are exposed to provide a direct path for current from the shield layer 122 to the tissue or from the shield layer 122 to a ground connection at the device 102.


Thus, the lead 110 may be manufactured in a conventional manner and then the shield layer 122 and insulative layer 124 may be added as subsequent steps. Furthermore, the lead 110 may exist in inventory and may be retrieved from inventory for a retrofit of the shield layer 122 and insulative layer 124.



FIG. 2 shows one example of an implantable medical system 200 that includes the implantable medical device 102 coupled to an implantable medical lead extension 202 that is in turn coupled to the implantable medical lead 110. A proximal end 112 of the lead 110 is present within a distal connection block 208 of the extension 202 where electrical contacts 114 of the lead 110 are electrically connected to connectors 210 of the connection block 208 of the extension. A proximal end 204 of the extension 202 is coupled to the connection block 104 of the medical device 102 where electrical contacts 206 of the extension are electrically connected to connectors 106 of the connection block 104. The distal end 116 of the lead is routed to the stimulation site where the electrodes 118 on the distal end 116 provide the stimulation signals to the tissue and/or sense signals from the tissue. Electrical conductors are present inside the lead 110 to electrically connect the contacts 114 with the electrodes 118 and electrical conductors are present inside the extension 202 to electrically connect the connectors 210 to the contacts 206.


According to the embodiment shown, the extension 202 has an added shield layer 214 that has been applied to an existing outer layer 212 of the lead body of the extension 202. As with the shield layer 122 of the lead 110 in FIG. 1, this shield layer 214 of the extension 202 may be of various forms such as a tubular structure of braided conductive wires that have been overbraided atop the existing outer insulative layer 120, a tubular conductive foil structure, and the like. Where the shield layer 214 is a braided wire shield as shown in FIG. 2, the braid may be created with a variety of shield parameters as described above for the shield layer 122 and as described in U.S. patent application Ser. No. 13/264,067.


As can be seen, the added shield layer 202 is present with a proximal end of the shield layer 214 starting distally of a most distal proximal contact 206 and ending proximally of a most proximal distal connector 210 within the connector block 208. Likewise, an outer insulative layer 216 is applied atop the shield layer 214 with a proximal end of the outer insulative layer 216 starting distally of the most distal proximal contact 206 and ending proximally of the most proximal distal connector 210 to thereby entirely cover the added shield layer 214. This prevents exposure of the added shield layer 214 to the tissue surrounding the extension 202.


While the shield layer 214 is not in direct contact with the tissue along the length of the extension 202, high frequency RF energy coupled onto the shield layer 214, such as during an MRI scan, may capacitively couple to the surrounding tissue to dissipate the RF energy over the length of the shield layer 214. Thus, there is a significant amount of tissue where the RF energy is being dissipated for the extension, rather than a small amount of tissue where the electrodes 118 of the lead 110 are located. Furthermore, if desired, ground rings could be added atop the shield layer 214 where the ground rings are exposed to provide a direct path for current from the shield layer 214 to the tissue or from the shield layer 214 to a ground connection at the device 102.


Thus, the extension 202 may also be manufactured in a conventional manner and then the shield layer 214 and insulative layer 216 may be added as subsequent steps. Furthermore, the extension 202 may exist in inventory and may be retrieved from inventory for a retrofit of the shield layer 214 and insulative layer 216.


As shown in FIG. 2, the lead 110 attached to the extension 202 also includes the added shield layer 122. However, the extension 202 having the shield layer 214 may be used in conjunction with other leads such as leads that have integral shields or even leads that have no shield where the risk of RF coupling to the lead is not as problematic. Similarly, the lead 110 having the added shield layer 122 may be used in conjunction with other extensions including extensions that have integral shields rather than shields that have been added.



FIG. 3 shows a cross-section of a lead 110 or lead extension 202. The original construction of the lead 110 or lead extension 202 includes the lead body 120, 212. Electrical conductors 302 are present within the lead body 120, 212. The lead body 120, 221 may define a lumen 304 that the conductors 302 pass through when extending from the proximal end to the distal end. The electrical conductors 302 are electrically coupled to the proximal contacts and the distal electrode of the lead or distal connector of the lead extension.


The shield layer 122, 214 is then added about the lead body 120, 212. The shield layer 122, 214 may be added by sliding a loose fitting shield layer, such as the tubular braid of wires or a tubular foil on the lead body 120, 212. Alternatively, the shield layer may be extruded or braided directly onto the lead body 120, 212. This alternative is discussed in more detail below with reference to FIG. 5.


The outer insulative layer 124, 216 is then added over the shield layer 122, 214. The outer insulative layer 124 may be extruded onto the shield layer 122, 214 or may be a tubular structure such as a polyurethane heat shrink tube that fits loosely over the shield layer 122, 214. Once heated the heat shrink tube then shrinks to tightly fit against the shield layer 122, 214 and the lead body 120, 212 which fixes the position of the shield layer 122, 214 and also provides separation of the shield layer 122, 214 from the exterior conditions.


One example of operations 400 for constructing the lead or lead extension with the added shield layer is shown in FIG. 4. In this example, the shield layer is a braided tubular structure that is created by braiding the wires directly onto the lead body. At an operation 402, the lead body of the lead or lead extension is loaded into a braiding machine that ordinarily braids wires onto a mandrel. However, the lead body acts as the mandrel. The braid is then created onto the lead body between the proximal contact and the distal electrode or distal connector housing at an operation 404. In this example, a heat shrink tubing is used to provide the outer insulative layer. This heat shrink tubing is positioned by sliding the tubing over the braided shield layer now present on the lead body at an operation 406. Heat is then applied to the heat shrink tubing to cause it to shrink against the braided shield layer at an operation 408.


An example of the braiding machine configuration that may be used to complete the operations 402 and 404 of FIG. 4 is shown in FIG. 5. The conventional braiding machine 500 includes a spool support 504, individual spools of wire 502, and a braiding mechanism 506 that guides the wires into the braided configuration onto a mandrel. However, in this configuration, the lead 110 or lead extension 202 is fed through the braiding mechanism 506 in place of a mandrel. As the lead 110 or lead extension 202 moves to the right as shown, the wires are braided onto the lead body.



FIG. 6 shows another embodiment of a lead or lead extension 600 that has a shield layer 604 that has been added to the lead body 602. Prior to application of the outer insulative layer 608, a shield terminator 606 is positioned over the end of the shield layer 604. The shield terminator 606 may be of various forms. For instance, the shield terminator 606 may be a ring that is crimped onto the end of the shield layer 604. This is particularly beneficial for a braided wire shield layer as the ring terminator 606 contains the braid wires and prevents the braid wires from migrating radially through the insulative layer 608. As another example, the terminator 606 may be a polyurethane heat shrink terminator that covers only the end portion of the shield layer 604 and is heated to contain the end of the shield layer 604.


As shown, the insulative layer 608 is applied over the shield layer 604 and may also be applied over the shield terminator 606. Where the terminator 606 is a heat shrink terminator, the result is a heat shrink terminator then covered by an outer insulative layer 608 that may also be a heat shrink tubing.


Alternatively, where the terminator is a biocompatible conductive material such as a biocompatible metal ring, the insulative layer 608 may be stopped prior to covering the shield terminator 606 which allows the shield terminator 606 be exposed to the external conditions. This allows the terminator 606 to provide a ground path from the shield layer to a ground connector of the implantable device 102 that electrically couples to the terminator 606 or a ground path directly to tissue in contact with the terminator 606.



FIG. 7 shows an alteration to the operations 400 of FIG. 4 in order to provide the metal ring terminator. Immediately after operation 404 and prior to operation 406 of FIG. 4, the metal ring is placed over the end of the shield layer and is then crimped tightly against the shield layer at an operation 702. The outer insulative layer may then be positioned over the shield layer at the operation 406 as described above in relation to FIG. 4.



FIG. 8 shows an alteration to the operations 400 of FIG. 4 in order to provide the heat shrink terminator. Immediately after operation 404 and prior to operation 406 of FIG. 4, the heat shrink terminator is placed over the end of the shield layer at an operation 802. Heat is then applied to the heat shrink terminator at an operation 804 to cause the heat shrink terminator to tighten against the end of the shield layer. The outer insulative layer may then be positioned over the shield layer at the operation 406 as described above in relation to FIG. 4.



FIG. 9 shows a cross-section of an alternative embodiment that adds an inner insulative layer onto the lead body of a lead 110′ or lead extension 202′ prior to adding the shield layer. This embodiment may be useful where the lead body of the existing lead 110′ or lead extension 202′ is a material that may not be appropriate for receiving the shield layer directly due to being too soft or lacking bonding strength to the metal of the shield layer and/or polymers of the outer insulative layer. For instance, the lead body 120′, 212′ may be a silicone material to provide a very high degree of flexibility. However, it may be appropriate to shield a portion of the lead body 120′, 212′ where the high degree of flexibility is not needed. For example, a lead being used for deep brain stimulation may need to be very flexible at the entry point to the brain where a sharp bend of the lead body is necessary. Yet it may be acceptable for that lead to be stiffer in the area where the lead passes by the ear. Therefore, in that section that may be stiffer, the inner insulative layer 902 may be added to the lead body 120′, 212′ where that inner insulative layer 902 may be a material such as a polyurethane heat shrink tubing.


The shield layer 122, 214 is applied onto the inner insulative layer 902 as in the prior embodiments. The inner insulative layer 902 protects the lead body 120′, 212′ which may be more vulnerable to damage from the shield layer 122, 214 due to being a very soft and flexible material. The outer insulative layer 124, 216 is then applied over the shield layer 122, 214 as discussed above for the prior embodiments.



FIG. 10 shows an alteration to the operations 400 of FIG. 4 in order to provide the inner insulative layer. Immediately before the operation 402 of FIG. 4, the heat shrink tubing which acts as the inner insulative layer 902 in this example is placed over the lead body 120′, 212′ at an operation 1002. Heat may be applied to the heat shrink tubing at this point or alternatively may be heated when heating the outer insulative layer. The lead 110′ or lead extension 202′ may then be positioned into the braiding machine at the operation 402 as described above in relation to FIG. 4 or may otherwise receive the shield layer 122, 214 and the operations of FIG. 4 proceed. The resulting lead or extension maintains flexibility where needed while being shielded in other areas.


While embodiments have been particularly shown and described, it will be understood by those skilled in the art that various other changes in the form and details may be made therein without departing from the spirit and scope of the invention.

Claims
  • 1. An implantable medical lead, comprising: an insulative linear lead body defining a lumen;a conductor within the lumen;a proximal contact coupled to a proximal area of the lead body and in direct contact with the proximal area of the lead body;a distal electrode coupled to a distal area of the lead body, with the conductor electrically coupling the proximal contact to the distal electrode;an inner insulative layer coupled to and in direct contact with the outer surface of the linear lead body over the complete circumference of the outer surface of the lead body;a shield layer positioned about and in direct contact with the inner insulative layer and between the proximal contact and the distal electrode; andan outermost insulative layer positioned about and in direct contact with the shield layer and between the proximal contact and the distal electrode.
  • 2. The implantable medical lead of claim 1, wherein the shield layer comprises braided wires on the outer surface of the inner insulative layer.
  • 3. The implantable medical lead of claim 1, wherein the shield layer comprises tantalum.
  • 4. The implantable medical lead of claim 1, wherein the outermost insulative layer comprises a polymer heat shrink tubing.
  • 5. The implantable medical lead of claim 1, further comprising a terminator positioned on an end of the shield layer.
  • 6. The implantable medical lead of claim 1, wherein the distal electrode is in direct contact with the distal area of the lead body.
  • 7. The implantable medical lead of claim 1, wherein the outer insulative layer has a diameter and wherein the diameter of the outer insulative layer exceeds a diameter of the proximal contact.
  • 8. The implantable medical lead of claim 1, wherein the outer insulative layer has a diameter and wherein the diameter of the outer insulative layer exceeds a diameter of the distal electrode.
  • 9. The implantable medical lead of claim 1, wherein the shield layer has a diameter and wherein the diameter of the shield layer exceeds a diameter of the proximal contact.
  • 10. The implantable medical lead of claim 1, wherein the shield layer has a diameter and wherein the diameter of the shield layer exceeds a diameter of the distal electrode.
  • 11. An implantable medical lead, comprising: an insulative linear lead body defining a lumen;a conductor within the lumen;a proximal contact coupled to a proximal area of the lead body;a distal electrode coupled to a distal area of the lead body and in direct contact with the distal area of the lead body, with the conductor electrically coupling the proximal contact to the distal electrode;an inner insulative layer coupled to and in direct contact with the outer surface of the linear lead body over the complete circumference of the outer surface of the lead body;a shield layer positioned about and in direct contact with the inner insulative layer and between the proximal contact and the distal electrode; andan outermost insulative layer positioned about and in direct contact with the shield layer and between the proximal contact and the distal electrode.
  • 12. The implantable medical lead of claim 11, wherein the proximal contact is in direct contact with the proximal area of the lead body.
  • 13. The implantable medical lead of claim 11, wherein the outer insulative layer has a diameter and wherein the diameter of the outer insulative layer exceeds a diameter of the proximal contact.
  • 14. The implantable medical lead of claim 11, wherein the outer insulative layer has a diameter and wherein the diameter of the outer insulative layer exceeds a diameter of the distal electrode.
  • 15. The implantable medical lead of claim 11, wherein the shield layer has a diameter and wherein the diameter of the shield layer exceeds a diameter of the proximal contact.
  • 16. The implantable medical lead of claim 11, wherein the shield layer has a diameter and wherein the diameter of the shield layer exceeds a diameter of the distal electrode.
US Referenced Citations (472)
Number Name Date Kind
2433480 Rendich Dec 1947 A
2487038 Jasper Nov 1949 A
3788329 Friedman Jan 1974 A
3842485 Bemert Oct 1974 A
3915174 Preston Oct 1975 A
4033355 Amundson Jul 1977 A
4038990 Thompson Aug 1977 A
4214804 Little Jul 1980 A
4220813 Kyle Sep 1980 A
4280507 Rosenberg Jul 1981 A
4320763 Money Mar 1982 A
4350169 Dutcher Sep 1982 A
4383225 Mayer May 1983 A
4403824 Scott Sep 1983 A
4441498 Nordling Apr 1984 A
4628942 Sweeney et al. Dec 1986 A
4683895 Pohndorf Aug 1987 A
4711027 Harris Dec 1987 A
4726379 Altman et al. Feb 1988 A
4852585 Heath Aug 1989 A
4906241 Noddin Mar 1990 A
4920980 Jackowski May 1990 A
4922607 Doan et al. May 1990 A
4934380 De Toledo Jun 1990 A
4947866 Lessar et al. Aug 1990 A
4951672 Buchwald et al. Aug 1990 A
4991583 Silvian Feb 1991 A
5003992 Holleman Apr 1991 A
5005587 Scott Apr 1991 A
5012045 Sato Apr 1991 A
5018523 Bach, Jr. et al. May 1991 A
5020544 Dahl et al. Jun 1991 A
5020545 Soukup Jun 1991 A
5036862 Pohndorf Aug 1991 A
5040544 Lessar et al. Aug 1991 A
5063932 Dahl et al. Nov 1991 A
5197468 Proctor et al. Mar 1993 A
5213111 Cook et al. May 1993 A
5217010 Tsitlik et al. Jun 1993 A
5231078 Riebman et al. Jul 1993 A
5243996 Hall Sep 1993 A
5246438 Langberg Sep 1993 A
5260128 Ishii et al. Nov 1993 A
5265608 Lee et al. Nov 1993 A
5265623 Kroll et al. Nov 1993 A
5271417 Swanson et al. Dec 1993 A
5308664 House et al. May 1994 A
5314459 Swanson et al. May 1994 A
5323776 Blakely et al. Jun 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5349133 Rogers Sep 1994 A
5360441 Otten Nov 1994 A
5366496 Dahl et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5374286 Morris Dec 1994 A
5374778 Hashimoto et al. Dec 1994 A
5417719 Hull et al. May 1995 A
5456705 Morris Oct 1995 A
5458629 Baudino et al. Oct 1995 A
5458631 Xavier Oct 1995 A
5466252 Soukup et al. Nov 1995 A
5473812 Morris et al. Dec 1995 A
5476496 Strandberg et al. Dec 1995 A
5485667 Kleshinski Jan 1996 A
5500013 Buscemi et al. Mar 1996 A
5504274 McCabe et al. Apr 1996 A
5514172 Mueller May 1996 A
5515848 Corbett, III et al. May 1996 A
5523534 Meister et al. Jun 1996 A
5523578 Herskovic Jun 1996 A
5527348 Winkler Jun 1996 A
5534018 Wahlstrand Jul 1996 A
5552565 Cartier et al. Sep 1996 A
5571157 McConnell Nov 1996 A
5572594 DeVoe et al. Nov 1996 A
5591218 Jacobson Jan 1997 A
5594304 Graber Jan 1997 A
5606981 Tartacower et al. Mar 1997 A
5609622 Soukup et al. Mar 1997 A
5628780 Helland et al. May 1997 A
5629622 Scampini May 1997 A
5643254 Scheldrup et al. Jul 1997 A
5649965 Pons et al. Jul 1997 A
5662697 Li et al. Sep 1997 A
5676659 McGurk Oct 1997 A
5676694 Boser et al. Oct 1997 A
5683435 Truex et al. Nov 1997 A
5683444 Huntley et al. Nov 1997 A
5697909 Eggers et al. Dec 1997 A
5697958 Paul et al. Dec 1997 A
5702437 Baudino Dec 1997 A
5706826 Schwager Jan 1998 A
5722998 Prutchi et al. Mar 1998 A
5727552 Ryan Mar 1998 A
5751539 Stevenson et al. May 1998 A
5766232 Grevious et al. Jun 1998 A
5782241 Felblinger et al. Jul 1998 A
5795341 Samson Aug 1998 A
5807258 Cimochowski et al. Sep 1998 A
5814076 Brownlee Sep 1998 A
5827997 Chung et al. Oct 1998 A
5830136 Delonzor et al. Nov 1998 A
5842966 Markoll Dec 1998 A
5842986 Avrin et al. Dec 1998 A
5851226 Skubitz et al. Dec 1998 A
5897584 Herman Apr 1999 A
5905627 Brendel et al. May 1999 A
5927345 Samson Jul 1999 A
5931861 Werner et al. Aug 1999 A
5954760 Jarl Sep 1999 A
5964705 Truwit et al. Oct 1999 A
5968087 Hess Oct 1999 A
5970429 Martin Oct 1999 A
5942966 Markoll Dec 1999 A
6004269 Crowley Dec 1999 A
6016447 Juran et al. Jan 2000 A
6024703 Zanelli et al. Feb 2000 A
6032063 Hoar et al. Feb 2000 A
6033408 Gage et al. Mar 2000 A
6055457 Bonner Apr 2000 A
6101417 Vogel et al. Aug 2000 A
6103037 Wilson Aug 2000 A
6108582 Fischer, Sr. Aug 2000 A
6132390 Cookston et al. Oct 2000 A
6141593 Patag Oct 2000 A
6143013 Samson et al. Nov 2000 A
6152746 Brown Nov 2000 A
6156029 Mueller Dec 2000 A
6195267 MacDonald et al. Feb 2001 B1
6198807 DeSena Mar 2001 B1
6198972 Hartlaub et al. Mar 2001 B1
6209764 Hartlaub et al. Apr 2001 B1
6240322 Peterfeso May 2001 B1
6258071 Brookes Jul 2001 B1
6265466 Glatkowski Jul 2001 B1
6269148 Jessop et al. Jul 2001 B1
6284971 Atalar et al. Sep 2001 B1
6302740 Holmstrom Oct 2001 B1
6348070 Teissl et al. Feb 2002 B1
6424234 Stevenson Jul 2002 B1
6471699 Fleischman et al. Oct 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494916 Babalola et al. Dec 2002 B1
6501991 Honeck et al. Dec 2002 B1
6503648 Wang Jan 2003 B1
6506972 Wang Jan 2003 B1
6529774 Greene Mar 2003 B1
6538191 MacDonald Mar 2003 B1
6583361 Clouet Jun 2003 B2
6606521 Paspa et al. Aug 2003 B2
6640137 MacDonald Oct 2003 B2
6648690 Saito et al. Nov 2003 B2
6660116 Wolf et al. Dec 2003 B2
6671544 Baudino Dec 2003 B2
6671554 Gibson et al. Dec 2003 B2
6673999 Wang et al. Jan 2004 B1
6675033 Lardo et al. Jan 2004 B1
6689835 Amarasekera et al. Feb 2004 B2
6695761 Oschman et al. Feb 2004 B2
6708051 Durousseau Mar 2004 B1
6711440 Deal et al. Mar 2004 B2
6712844 Pacetti et al. Mar 2004 B2
6713671 Wang et al. Mar 2004 B1
6718203 Weiner et al. Apr 2004 B2
6718207 Connelly Apr 2004 B2
6725092 MacDonald et al. Apr 2004 B2
6735471 Hill et al. May 2004 B2
6741892 Meadows et al. May 2004 B1
6743055 Flynn Jun 2004 B1
6750055 Connelly et al. Jun 2004 B1
6757566 Weiner et al. Jun 2004 B2
6760628 Weiner et al. Jul 2004 B2
6763268 MacDonald et al. Jul 2004 B2
6765144 Wang et al. Jul 2004 B1
6768053 Wang et al. Jul 2004 B1
6778856 Connelly et al. Aug 2004 B2
6792316 Sass Sep 2004 B2
6793642 Connelly et al. Sep 2004 B2
6795730 Connelly et al. Sep 2004 B2
6795736 Connelly et al. Sep 2004 B2
6799067 Pacetti Sep 2004 B2
6799069 Weiner et al. Sep 2004 B2
6815609 Wang et al. Nov 2004 B1
6819954 Connelly Nov 2004 B2
6819958 Weiner et al. Nov 2004 B2
6844492 Wang et al. Jan 2005 B1
6845259 Pacetti et al. Jan 2005 B2
6845267 Harrison et al. Jan 2005 B2
6846985 Wang et al. Jan 2005 B2
6850805 Connelly et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6863653 Zanelli et al. Mar 2005 B1
6864418 Wang et al. Mar 2005 B2
6869683 Sakurai et al. Mar 2005 B2
6871091 Wilkinson et al. Mar 2005 B2
6872882 Fritz Mar 2005 B2
6875180 Weiner et al. Apr 2005 B2
6879861 Benz et al. Apr 2005 B2
6882519 Uzawa et al. Apr 2005 B2
6895280 Meadows et al. May 2005 B2
6901287 Davis et al. May 2005 B2
6901290 Foster et al. May 2005 B2
6906256 Wang Jun 2005 B1
6920361 Williams Jul 2005 B2
6922590 Whitehurst Jul 2005 B1
6925328 Foster et al. Aug 2005 B2
6930242 Helfer Aug 2005 B1
6937906 Terry et al. Aug 2005 B2
6944489 Zeiljemaker et al. Sep 2005 B2
6949929 Gray et al. Sep 2005 B2
6954674 Connelly Oct 2005 B2
6968235 Belden et al. Nov 2005 B2
6968236 Hagele Nov 2005 B2
6971391 Wang et al. Dec 2005 B1
6980865 Wang et al. Dec 2005 B1
6982378 Dickson Jan 2006 B2
6985775 Reinke et al. Jan 2006 B2
6993387 Connelly et al. Jan 2006 B2
6999818 Stevenson et al. Feb 2006 B2
6999821 Jenney et al. Feb 2006 B2
7001369 Griffin et al. Feb 2006 B2
7013174 Connelly et al. Mar 2006 B2
7013180 Villaseca et al. Mar 2006 B2
7015392 Dickenson Mar 2006 B1
7015393 Weiner Mar 2006 B2
7047084 Erickson May 2006 B2
7050855 Zeijlemaker et al. May 2006 B2
7058192 Muller et al. Jun 2006 B2
7076283 Cho et al. Jul 2006 B2
7076302 Scheiner Jul 2006 B2
7082328 Funke Jul 2006 B2
7082337 Sommer et al. Jul 2006 B2
7103413 Swanson Sep 2006 B2
7113827 Silvestri Sep 2006 B2
7115134 Chambers Oct 2006 B2
7118693 Glatkowski et al. Oct 2006 B2
7123013 Gray Oct 2006 B2
7125409 Truckai et al. Oct 2006 B2
7162302 Wang et al. Jan 2007 B2
7174219 Wahlstrand et al. Feb 2007 B2
7187980 Osypka et al. Mar 2007 B2
7233825 Jorgenson et al. Jun 2007 B2
7257449 Bodner Aug 2007 B2
7282260 LeGrande et al. Oct 2007 B2
7286871 Cohen Oct 2007 B2
7286882 Cole Oct 2007 B2
7292894 Belden Nov 2007 B2
7294785 Uutela et al. Nov 2007 B2
7319901 Dublin Jan 2008 B2
7363090 Halperin Apr 2008 B2
7389148 Morgan Jun 2008 B1
7540865 Griffin et al. Jun 2009 B2
7548788 Chinn et al. Jun 2009 B2
7591831 Parsonage et al. Sep 2009 B2
7674972 Gladd et al. Mar 2010 B2
7711436 Stone May 2010 B2
7729777 Gray et al. Jun 2010 B2
7738942 Weiner Jun 2010 B2
7813811 Wingeier et al. Oct 2010 B2
7819826 Diederich et al. Oct 2010 B2
7822484 Zhao et al. Oct 2010 B1
7828833 Haverkost Nov 2010 B2
7844343 Wahlstrand Nov 2010 B2
7844344 Wahlstrand Nov 2010 B2
7853332 Olsen Dec 2010 B2
7877150 Hoegh et al. Jan 2011 B2
7904178 Williams Mar 2011 B2
7917213 Bulkes Mar 2011 B2
7933652 Phillips Apr 2011 B2
8007440 Magnin et al. Aug 2011 B2
8027736 Wahlstrand Sep 2011 B2
8036756 Swoyer et al. Oct 2011 B2
8048060 Griffin et al. Nov 2011 B2
8055351 Atalar et al. Nov 2011 B2
8106657 Sakellariou et al. Jan 2012 B2
8170691 Eckerdal May 2012 B2
8202259 Evans et al. Jun 2012 B2
8246643 Nita Aug 2012 B2
8275464 Li et al. Sep 2012 B2
8280526 Wahlstrand Oct 2012 B2
8483842 Alexander et al. Jul 2013 B2
8620455 Alexander et al. Dec 2013 B2
8676340 Wahlstrand Mar 2014 B2
8744598 Alexander et al. Jun 2014 B2
8788061 Mehdizadeth Jul 2014 B2
8805534 Olsen Aug 2014 B2
8903504 Hegland Dec 2014 B2
9002474 Olsen Apr 2015 B2
9037263 Marshall May 2015 B2
9044593 Li Jun 2015 B2
20010044646 Marshall et al. Nov 2001 A1
20020032468 Hill Mar 2002 A1
20020038135 Connelly et al. Mar 2002 A1
20020058978 Sass May 2002 A1
20020183438 Amarasekera et al. May 2002 A1
20020082673 Benz et al. Jun 2002 A1
20020106918 Saito et al. Aug 2002 A1
20020111659 Davis et al. Aug 2002 A1
20020111663 Dahl et al. Aug 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020128689 Connelly et al. Sep 2002 A1
20020128691 Connelly Sep 2002 A1
20020133086 Connelly et al. Sep 2002 A1
20020133199 MacDonald et al. Sep 2002 A1
20020133200 Weiner et al. Sep 2002 A1
20020133201 Connelly et al. Sep 2002 A1
20020133202 Connelly et al. Sep 2002 A1
20020133208 Connelly Sep 2002 A1
20020133211 Weiner et al. Sep 2002 A1
20020133216 Connelly et al. Sep 2002 A1
20020138102 Weiner et al. Sep 2002 A1
20020138107 Weiner et al. Sep 2002 A1
20020138108 Weiner et al. Sep 2002 A1
20020138110 Connelly et al. Sep 2002 A1
20020138112 Connelly et al. Sep 2002 A1
20020143377 Wessman et al. Oct 2002 A1
20020183740 Edwards et al. Dec 2002 A1
20020183822 Bodner Dec 2002 A1
20020188345 Pacetti Dec 2002 A1
20030009207 Paspa et al. Jan 2003 A1
20030014080 Baudino Jan 2003 A1
20030036776 Foster et al. Feb 2003 A1
20030044623 Sakurai et al. Mar 2003 A1
20030045920 Belden et al. Mar 2003 A1
20030060732 Jacobsen et al. Mar 2003 A1
20030083570 Cho et al. May 2003 A1
20030083723 Wilkinson et al. May 2003 A1
20030083726 Zeijlemaker et al. May 2003 A1
20030093107 Parsonage et al. May 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030117787 Nakauchi Jun 2003 A1
20030120148 Pacetti Jun 2003 A1
20030120197 Kaneko et al. Jun 2003 A1
20030135114 Pacetti et al. Jul 2003 A1
20030139794 Jenney et al. Jul 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030140931 Zeijlemaker Jul 2003 A1
20030144704 Terry Jul 2003 A1
20030144705 Funke Jul 2003 A1
20030144716 Reinke et al. Jul 2003 A1
20030144717 Hegele Jul 2003 A1
20030144718 Zeijlemaker Jul 2003 A1
20030144719 Zeijlemaker Jul 2003 A1
20030144720 Villaseca et al. Jul 2003 A1
20030144721 Villaseca et al. Jul 2003 A1
20030167052 Lee et al. Sep 2003 A1
20030204217 Greatbatch Oct 2003 A1
20030225331 Diederich et al. Dec 2003 A1
20040020674 McFadden et al. Feb 2004 A1
20040024442 Sowinski et al. Feb 2004 A1
20040028859 LeGrande et al. Feb 2004 A1
20040068307 Goble Apr 2004 A1
20040071949 Glatkowski et al. Apr 2004 A1
20040088012 Kroll et al. May 2004 A1
20040106958 Mathis et al. Jun 2004 A1
20040162600 Williams Aug 2004 A1
20040167443 Shireman et al. Aug 2004 A1
20040173368 Dickson Sep 2004 A1
20040199069 Connelly et al. Oct 2004 A1
20040220549 Dittman et al. Nov 2004 A1
20040249428 Wang et al. Dec 2004 A1
20040251042 Weiner et al. Dec 2004 A1
20040263172 Gray et al. Dec 2004 A1
20040263173 Gray Dec 2004 A1
20040263174 Gray et al. Dec 2004 A1
20040267328 Duffin Dec 2004 A1
20050065587 Gryzwa Mar 2005 A1
20050070972 Wahlstrand Mar 2005 A1
20050080471 Chitre et al. Apr 2005 A1
20050113876 Weiner May 2005 A1
20050115624 Walak Jun 2005 A1
20050137664 Sommer et al. Jun 2005 A1
20050145307 Shireman et al. Jul 2005 A1
20050159661 Connelly et al. Jul 2005 A1
20050182471 Wang Aug 2005 A1
20050222642 Przybyszewski Oct 2005 A1
20050222647 Wahlstrand Oct 2005 A1
20050222656 Wahlstrand Oct 2005 A1
20050222657 Wahlstrand Oct 2005 A1
20050222658 Hoegh et al. Oct 2005 A1
20050222659 Olsen Oct 2005 A1
20060030918 Chinn et al. Feb 2006 A1
20060036306 Heist et al. Feb 2006 A1
20060079926 Desai et al. Apr 2006 A1
20060089680 Bruchmann et al. Apr 2006 A1
20060095078 Tronnes May 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060155270 Hancock Jul 2006 A1
20060167522 Malinowski Jul 2006 A1
20060167527 Malinowski Jul 2006 A1
20060200218 Wahlstrand Sep 2006 A1
20060224207 Dublin Oct 2006 A1
20060247747 Olsen Nov 2006 A1
20060247748 Wahlstrand Nov 2006 A1
20070021811 D'Aquanni et al. Jan 2007 A1
20070106332 Denker May 2007 A1
20070123805 Shireman et al. May 2007 A1
20070129779 Ayre Jun 2007 A1
20070168008 Olsen Jul 2007 A1
20070185556 Williams Aug 2007 A1
20070208383 Williams Sep 2007 A1
20070293924 Belden et al. Dec 2007 A1
20080033497 Bulkes Feb 2008 A1
20080039709 Karmarkar Feb 2008 A1
20080058715 Houser et al. Mar 2008 A1
20080154326 Clyne Jun 2008 A1
20080183263 Alexander Jul 2008 A1
20080195186 Li Aug 2008 A1
20080195187 Li Aug 2008 A1
20080215008 Nance et al. Sep 2008 A1
20080242944 Sharma Oct 2008 A1
20080243081 Nance et al. Oct 2008 A1
20080243218 Bottomley Oct 2008 A1
20080262582 Alexander Oct 2008 A1
20080262584 Bottomley Oct 2008 A1
20080269863 Alexander Oct 2008 A1
20080287804 Nita Nov 2008 A1
20090171421 Atalar Jul 2009 A1
20090204192 Carlton Aug 2009 A1
20090221970 Spinoza Sep 2009 A1
20090228074 Edgell et al. Sep 2009 A1
20090234402 Marshall Sep 2009 A1
20090240235 Murata Sep 2009 A1
20090259272 Reddy Oct 2009 A1
20090270956 Vase Oct 2009 A1
20090287189 Suwito Nov 2009 A1
20100069743 Sheetz et al. Mar 2010 A1
20100100164 Johnson et al. Apr 2010 A1
20100137957 Eckerdal Jun 2010 A1
20100145426 Stone Jun 2010 A1
20100198327 Helland Aug 2010 A1
20100256528 Lippert et al. Oct 2010 A1
20100256604 Lippert et al. Oct 2010 A1
20100268310 Bonde et al. Oct 2010 A1
20100331938 Sommer Dec 2010 A1
20110015713 Min Jan 2011 A1
20110034983 Min Feb 2011 A1
20110071599 Olsen Mar 2011 A1
20110071604 Wahlstrand Mar 2011 A1
20110071605 Wahlstrand Mar 2011 A1
20110112615 Hoegh et al. May 2011 A1
20110230943 Johnson et al. Sep 2011 A1
20110251487 Magnin et al. Oct 2011 A1
20110319905 Palme et al. Dec 2011 A1
20120010689 Wahlstrand Jan 2012 A1
20120035616 Olsen et al. Feb 2012 A1
20120035694 Olsen Feb 2012 A1
20120035695 Olsen et al. Feb 2012 A1
20120035696 Kern Feb 2012 A1
20120035697 Stone Feb 2012 A1
20120035951 Goetz Feb 2012 A1
20120041528 Mehdizadeh Feb 2012 A1
20120041529 Olsen Feb 2012 A1
20120046722 Olsen Feb 2012 A1
20120635696 Kern Feb 2012
20120053664 Hegland Mar 2012 A1
20120059467 Drew Mar 2012 A1
20120130461 Olsen May 2012 A1
20120330383 Wahlstrand Dec 2012 A1
20130282088 Bondhus Oct 2013 A1
20130296991 Alexander et al. Nov 2013 A1
20140107746 Alexander et al. Apr 2014 A1
20140200643 Wahlstrand Jul 2014 A1
20140288626 Alexander et al. Sep 2014 A1
20140345132 Mehdizadeh et al. Nov 2014 A1
20140350654 Olsen et al. Nov 2014 A1
20150082618 Hegland Mar 2015 A1
20150170792 Alford Jun 2015 A1
20150374977 Howard et al. Dec 2015 A1
Foreign Referenced Citations (81)
Number Date Country
0617978 Oct 1994 EP
0624383 Nov 1994 EP
0713714 May 1996 EP
0760196 Mar 1997 EP
0920239 Jun 1999 EP
1273922 Jan 2003 EP
1424095 Jun 2004 EP
1466576 Oct 2004 EP
1625875 Feb 2006 EP
1632265 Mar 2006 EP
1935449 Jun 2008 EP
2429154 Feb 2007 GB
07255863 Oct 1995 JP
11086641 Mar 1999 JP
WO95032673 Dec 1995 WO
WO96016694 Jun 1996 WO
WO96028951 Sep 1996 WO
WO97041923 Nov 1997 WO
WO98048896 Nov 1998 WO
WO99010035 Mar 1999 WO
WO99019020 Apr 1999 WO
WO99060370 Nov 1999 WO
WO00027279 May 2000 WO
WO01080940 Nov 2001 WO
WO02000292 Jan 2002 WO
WO02083236 Oct 2002 WO
WO03037429 May 2003 WO
WO03061755 Jul 2003 WO
WO03063946 Aug 2003 WO
WO03063948 Aug 2003 WO
WO03063952 Aug 2003 WO
WO03063953 Aug 2003 WO
WO03063954 Aug 2003 WO
WO03063955 Aug 2003 WO
WO03063956 Aug 2003 WO
WO03063957 Aug 2003 WO
WO03075797 Sep 2003 WO
WO03092326 Nov 2003 WO
WO03095022 Nov 2003 WO
WO04012809 Feb 2004 WO
WO04052448 Jun 2004 WO
WO04073040 Aug 2004 WO
WO05030322 Apr 2005 WO
WO05032654 Apr 2005 WO
WO05102444 Nov 2005 WO
WO05102445 Nov 2005 WO
WO05102446 Nov 2005 WO
WO05102447 Nov 2005 WO
WO06031317 Mar 2006 WO
WO06093685 Sep 2006 WO
WO06093686 Sep 2006 WO
WO06118640 Nov 2006 WO
WO06118641 Nov 2006 WO
WO07047966 Apr 2007 WO
WO07124273 Nov 2007 WO
WO07126657 Nov 2007 WO
WO07149757 Dec 2007 WO
WO08088568 Jul 2008 WO
WO08100839 Aug 2008 WO
WO08100840 Aug 2008 WO
WO08111986 Sep 2008 WO
WO08130409 Oct 2008 WO
WO08134196 Nov 2008 WO
WO08140376 Nov 2008 WO
WO09011440 Sep 2009 WO
WO09134901 Nov 2009 WO
WO10062988 Jun 2010 WO
WO10126871 Nov 2010 WO
WO10126877 Nov 2010 WO
WO10126884 Nov 2010 WO
WO10126887 Nov 2010 WO
WO10126935 Nov 2010 WO
WO10126939 Nov 2010 WO
WO10126943 Nov 2010 WO
WO10126946 Nov 2010 WO
WO10126949 Nov 2010 WO
WO10126975 Nov 2010 WO
WO10135440 Nov 2010 WO
WO11019416 Feb 2011 WO
WO12103419 Aug 2012 WO
WO13158189 Oct 2013 WO
Non-Patent Literature Citations (46)
Entry
PCT Application No. PCT/US2015/0471171 International Search Report and Written Opinion dated Oct. 1, 2015.
PCT/US2004/042081: Search Report and Written Opinion.
PCT/US2005/000322: Search Report and Written Opinion.
PCT/US2008/053540: Search Report and Written Opinion.
PCT/US2008/053541: Search Report and Written Opinion.
PCT/US2008/059358: Search Report and Written Opinion.
PCT/US2009/036461: Search Report and Written Opinion.
PCT/US2010/032516: Search Report and Written Opinion.
PCT/US2010/032526: Search Report and Written Opinion.
PCT/US2010/032543: Search Report and Written Opinion.
PCT/US2010/032560: Search Report and Written Opinion.
PCT/US2010/032567: Search Report and Written Opinion.
PCT/US2010/032666: Search Report and Written Opinion.
PCT/US2010/032671: Search Report and Written Opinion.
PCT/US2010/032675: Search Report and Written Opinion.
PCT/US2010/032682: Search Report and Written Opinion.
PCT/US2010/032719: Search Report and Written Opinion.
PCT/US2013/023637: Search Report and Written Opinion.
Baker et al., “Evaluation of Specific Absorption Rates as a Dosimeter of MRI-Related Implant Heating”, Journal of Magnetic Resonance Imaging 20:315-320 (2004).
Baker, K., et al., “Neurostimulation Systems: Assessment of Magnetic Field Interactions Associated with 1.5 and 3-Tesla MR Systems”, J. Magn. Reson. Imaging, Jan. 2005, 21(1);72-7.
Chung, D.D.L., “Carbon Fiber Composites”, 1994, chapter 1, p. 8, table 1.2, Elsevier, ISBN: 978-0-7506-9169-7.
Chung, D.D.L., Comparison of Submicron-Diameter Carbon Filaments and Conventional Carbon Fibers as Fillers in Composite Materials, Carbon 39 (2001) pp. 1119-1125, Elsevier Science Ltd.
Chung, D.D.L., Electromagnetic Interference Shielding Effectiveness of Carbon Materials, Carbon 29 (2001) pp. 279-285, Elsevier Science Ltd.
Engdahl, Tomi, “Ground Loop Basics.” Web Jan. 4, 2009, ePanorama.net www.epanorama.net/documents/groundloop/basics.html 28052.00 U.S. Appl. No. 11/739,787.
Finelli, D., et al., “MRI Imaging-Related Heating of Deep Brain Stimulation Electrodes: In Vitro Study”, AJNR Am. J. Neuroadiol 23:1, Nov./Dec. 2002.
Jou, W.S. “A Novel Structure of Woven Continuous-Carbon Fiber Composites with High Electromagnetic Shielding”, Journal of Electronic Materials, vol. 33, No. 3, Mar. 1, 2004, pp. 162-170(9), Minerals, Metals and Materials Society, http://findarticles.com/p/articIes/mi_qu3776/is_200403/ai_n9405_582/print.
Kolin, et al., “An Electromagnetic Catheter Flow Meter for Determination of Blood Flow in Major Arteries,” Department of Biophysics, Physiology, and Radiology, University of California School of Medicine (Los Angeles) Jan. 19, 1988, Proc. N.A.S. vol. 59, pp. 808-815.
Kolin, et al., “An Electromagnetic Intravascular Blood-Flow Sensor”, Department of Biophysics, University of California School of Medicine (Los Angeles), Mar. 20, 1967, Proc. N.A.S., vol. 57, pp. 1331-1337.
Kolin, et al., “Miniaturization of the Electromagnetic Blood Flow Meter and Its Use for the Recording of Circulatory Responses of Conscious Animals to Sensory Stimuli”, Department of Biophysics, University of California at Los Angeles, Aug. 1959, Proc. N.A.S. vol. 45(8), pp. 1312-1321.
Medtronic Activa Product Family and Procedure Solution Brochure, Medtronic, Inc, 2001.
Medtronic Neurostimulation Systems Brochure, Medtronic, Inc., 2002.
Oscor, Inc. Product Catalog, 2008 28052.00.
Quick et al., “Endourethral MRI”, Magnetic Resonance in Medicine, 45:138-146, 2001.
Rezai, A., et al., “Neurostimulation System Used for Deep Brain Stimulation (DBS): MR Safety Issues and Implications of Failing to Follow Safety Recommendations” Investigative Radiology, May 2004, vol. 39, Issue 5, pp. 300-303.
Rezai, A., et al., “Neurostimulation Systems for Deep Brain Stimulation In Vitro Evaluation of Magnetic Resonance Imaging-Related Healing at 1.5 Tesla”, Journal of Magnetic Reson. Imaging 2002; 15:241-50.
U.S. Appl. No. 14/807,323, filed Jul. 23, 2015.
U.S. Appl. No. 14/807,323 Restriction Requirement, dated Apr. 26, 2016.
U.S. Appl. No. 14/807,323, Response Filed Jun. 20, 2016.
U.S. Appl. No. 14/807,323, Non-Final Office Action, dated Jul. 13, 2016.
U.S. Appl. No. 14/807,323, Response Filed Oct. 13, 2016.
U.S. Appl. No. 14/807,323, Final Office Action, dated Feb. 1, 2017.
U.S. Appl. No. 14/807,323, Response Filed Apr. 21, 2017.
U.S. Appl. No. 14/807,323, Advisory Action, dated May 1, 2017.
U.S. Appl. No. 14/807,323, RCE Request and Response filed May 31, 2017.
U.S. Appl. No. 14/807,323 Non-Final Office Action, dated Jun. 27, 2017.
U.S. Appl. No. 14/807,323, Response Filed Sep. 27, 2017.
Related Publications (1)
Number Date Country
20160022983 A1 Jan 2016 US
Provisional Applications (1)
Number Date Country
62028120 Jul 2014 US